Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer

Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer

Abstract Immune checkpoint inhibitors (ICIs) plus chemotherapy have become the standard of care for first-line treatment of advanced non-small cell lung cancer (NSCLC) with EGFR/ALK negative. However, there is no clear second-line treatment option after first-line treatment failure. To investigate t...

Full description

Saved in:
Bibliographic Details
Main Authors: Guisen Yin, Xin Liu, Xiangtao Yu, Song Tan, Fen Liu
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Immune checkpoint inhibitors
Chemotherapy
First line
Non-small cell lung cancer
Progression
Survival
Online Access:https://doi.org/10.1038/s41598-024-83947-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-83947-7

Similar Items